Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

BMC Pulmonary Medicine

Table 6 Treatment-Emergent Adverse Events that Occurred in ≥ 3% of Patients (mITT Population), Number of Patients (%)

Body System	Tigecycline		Levofloxacin		Total		Fisher Exact
Adverse Event	(n = 216) N (%)		(n = 212) n (%)		(N = 428) N (%)		P-Value
Any adverse event	135	62.5	100	47.2	235	54.9	0.002*
Body as a whole	29	13.4	26	12.3	55	12.9	0.774
Headache	10	4.6	4	1.9	14	3.3	0.173
Digestive system	82	38.0	44	20.8	126	29.4	<0.001*
Diarrhoea	16	7.4	17	8.0	33	7.7	0.858
Nausea	58	26.9	18	8.5	76	17.8	<0.001*
Vomiting	36	16.7	14	6.6	50	11.7	0.001*
Haemic and lymphatic system	31	14.4	11	5.2	42	9.8	0.002*
Leukocytosis	15	6.9	2	0.9	17	4.0	0.002*
Thrombocythaemia	11	5.1	4	1.9	15	3.5	0.112
Metabolic and nutritional	20	9.3	26	12.3	46	10.7	0.351
ALT/SGPT increased	4	1.9	9	4.2	13	3.0	0.169
AST/SGOT increased	4	1.9	7	3.3	11	2.6	0.378
Hypokalaemia	1	0.5	8	3.8	9	2.1	0.019*

Abbreviation: ALT/SGPT = alanine aminotransferase (serum glutamic pyruvic transaminase); AST/SGOT = aspartate aminotransferase/serum glutamic oxaloacaetic transaminase.
Some subjects had more than 1 treatment-emergent adverse event.
*Significant between-group difference at 0.05 level.

ISSN: 1471-2466